The FDA approved a new safety warning for Depo-Provera alerting patients to a possible risk for a type of brain tumor called ...

The costs of an intracranial meningioma diagnosis can be substantial. Not only can this diagnosis lead to a lifetime of medical bills and other costs, but it can drastically reduce patients’ quality ...

At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which will take place in December 2026, ...

Recent scientific research has uncovered a significant association between the long-term use of Depo-Provera, a widely used injectable contraceptive, and the development of meningiomas, tumors ...

The MarketWatch News Department was not involved in the creation of this content. The number of lawsuits filed has tripled to over 1300 since May New US peer-reviewed study adds to body of research ...

Hundreds of women in the UK are considering taking legal action over fears a contraceptive jab has put them at risk of a potentially fatal brain tumour. Every month, about 10,000 prescriptions are ...

Please provide your email address to receive an email when new articles are posted on . Prolonged use of medroxyprogesterone acetate injection associated with a 5.6-fold increased risk. Use of ...

A study published on 29 June 2025 in international peer reviewed medical journal Expert Opinion on Drug Safety by Frey et al. has found that use of Pfizer’s Depo-Provera (DMPA) for more than one year ...

The decision comes as Pfizer faces lawsuits from more than 1000 women who say the company knew about the risks and didn’t warn them. The agency signed off last week on a label update for 2 versions of ...

PENSACOLA, Fla.--(BUSINESS WIRE)--At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which ...